The specter of generic challenges has long loomed over copyright’s iconic drug, PDE5 Inhibitor, sparking questions about the future of connected drug holdings. While initial periods saw impressive returns, the exclusivity expiration has opened the way for less expensive copies, likely reducing revenue and posing a genuine hazard for shareholders